| 摘要 |
The invention relates to medicine, in particular in experimental and clinical oncology and may be used for treatment of hormonosensitive tumors in women as well as in neglected cases at the loss of hormonosensitivity. The proposed pharmaceutical agent consists, in the case of treatment of hormonosensitive tumors at women, of a mechanical mixture of 2-4 g of DL-valine and a small nontherapeutic dose of 0.020-0.025 g of methyltestosterone, and, in the case of treatment of non-hormonosensitive tumors, of a mechanical mixture of 2-4 g of DL-valine, 0.005-0.010 g of methandrostenolone and 0.3-0.5 g of phtivazid. The technical result of using the proposed agent consists in that even in neglected cases the size of tumor decreases, sometimes up to complete resorption, the pain syndrome disappears, the life of incurable patients is substantially prolongated accompanied by a satisfactory subjective condition or, sometimes, by the resorption of the tumor. The use of the agent is not followed by any toxic effects, it increases even the antitumor resistance of the organism in the form of normalization of hemopoiesis, weight gain, substantial increase of the working capacity. The absence of side-effects and complications allows the agent to be used under ambulant conditions. |
